225 related articles for article (PubMed ID: 22647084)
1. Spin density projection-assisted R2 magnetic resonance imaging of the liver in the management of body iron stores in patients receiving multiple red blood cell transfusions: an audit and retrospective study in South Australia.
Brown GC; Patton WN; Tapp HE; Taylor DJ; St Pierre TG
Intern Med J; 2012 Sep; 42(9):990-6. PubMed ID: 22647084
[TBL] [Abstract][Full Text] [Related]
2. Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload.
Nolte F; Höchsmann B; Giagounidis A; Lübbert M; Platzbecker U; Haase D; Lück A; Gattermann N; Taupitz M; Baier M; Leismann O; Junkes A; Schumann C; Hofmann WK; Schrezenmeier H
Ann Hematol; 2013 Jan; 92(2):191-8. PubMed ID: 23073603
[TBL] [Abstract][Full Text] [Related]
3. Monitoring long-term efficacy of iron chelation treatment with biomagnetic liver susceptometry.
Fischer R; Piga A; Harmatz P; Nielsen P
Ann N Y Acad Sci; 2005; 1054():350-7. PubMed ID: 16339683
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of deferasirox at low and high iron burdens: results from the EPIC magnetic resonance imaging substudy.
Porter JB; Elalfy MS; Taher AT; Aydinok Y; Chan LL; Lee SH; Sutcharitchan P; Habr D; Martin N; El-Beshlawy A
Ann Hematol; 2013 Jan; 92(2):211-9. PubMed ID: 23086508
[TBL] [Abstract][Full Text] [Related]
5. Limitations of serum ferritin to predict liver iron concentration responses to deferasirox therapy in patients with transfusion-dependent thalassaemia.
Porter JB; Elalfy M; Taher A; Aydinok Y; Lee SH; Sutcharitchan P; El-Ali A; Han J; El-Beshlawy A
Eur J Haematol; 2017 Mar; 98(3):280-288. PubMed ID: 27859648
[TBL] [Abstract][Full Text] [Related]
6. Deferasirox for cardiac siderosis in β-thalassaemia major: a multicentre, open label, prospective study.
Piga A; Longo F; Origa R; Roggero S; Pinna F; Zappu A; Castiglioni C; Cappellini MD
Br J Haematol; 2014 Nov; 167(3):423-6. PubMed ID: 24976388
[No Abstract] [Full Text] [Related]
7. Transfusional Iron Overload in a Cohort of Children with Sickle Cell Disease: Impact of Magnetic Resonance Imaging, Transfusion Method, and Chelation.
Stanley HM; Friedman DF; Webb J; Kwiatkowski JL
Pediatr Blood Cancer; 2016 Aug; 63(8):1414-8. PubMed ID: 27100139
[TBL] [Abstract][Full Text] [Related]
8. Cardiac iron load and function in transfused patients treated with deferasirox (the MILE study).
Ho PJ; Tay L; Teo J; Marlton P; Grigg A; St Pierre T; Brown G; Badcock CA; Traficante R; Gervasio OL; Bowden DK
Eur J Haematol; 2017 Feb; 98(2):97-105. PubMed ID: 27537786
[TBL] [Abstract][Full Text] [Related]
9. Transfusional iron overload in children with sickle cell anemia on chronic transfusion therapy for secondary stroke prevention.
Kwiatkowski JL; Cohen AR; Garro J; Alvarez O; Nagasubramanian R; Sarnaik S; Thompson A; Woods GM; Schultz W; Mortier N; Lane P; Mueller B; Yovetich N; Ware RE;
Am J Hematol; 2012 Feb; 87(2):221-3. PubMed ID: 22120913
[TBL] [Abstract][Full Text] [Related]
10. Low serum ferritin levels are misleading for detecting cardiac iron overload and increase the risk of cardiomyopathy in thalassemia patients. The importance of cardiac iron overload monitoring using magnetic resonance imaging T2 and T2*.
Kolnagou A; Economides C; Eracleous E; Kontoghiorghes GJ
Hemoglobin; 2006; 30(2):219-27. PubMed ID: 16798647
[TBL] [Abstract][Full Text] [Related]
11. Deferasirox for iron chelation in multitransfused children with sickle cell disease; long-term experience in the East London clinical haemoglobinopathy network.
Tsouana E; Kaya B; Gadong N; Hemmaway C; Newell H; Simmons A; Whitmarsh S; Telfer P
Eur J Haematol; 2015 Apr; 94(4):336-42. PubMed ID: 25138173
[TBL] [Abstract][Full Text] [Related]
12. Iron chelation with deferasirox for the treatment of secondary hemosiderosis in pediatric oncology patients: a single-center experience.
Ktena YP; Athanasiadou A; Lambrou G; Adamaki M; Moschovi M
J Pediatr Hematol Oncol; 2013 Aug; 35(6):447-50. PubMed ID: 23669734
[TBL] [Abstract][Full Text] [Related]
13. Uses and limitations of serum ferritin, magnetic resonance imaging T2 and T2* in the diagnosis of iron overload and in the ferrikinetics of normalization of the iron stores in thalassemia using the International Committee on Chelation deferiprone/deferoxamine combination protocol.
Kolnagou A; Yazman D; Economides C; Eracleous E; Kontoghiorghes GJ
Hemoglobin; 2009; 33(5):312-22. PubMed ID: 19814677
[TBL] [Abstract][Full Text] [Related]
14. Iron chelation therapy for patients with sickle cell disease and iron overload.
Inati A; Khoriaty E; Musallam KM; Taher AT
Am J Hematol; 2010 Oct; 85(10):782-6. PubMed ID: 20721892
[No Abstract] [Full Text] [Related]
15. Ferritin trends do not predict changes in total body iron in patients with transfusional iron overload.
Puliyel M; Sposto R; Berdoukas VA; Hofstra TC; Nord A; Carson S; Wood J; Coates TD
Am J Hematol; 2014 Apr; 89(4):391-4. PubMed ID: 24347294
[TBL] [Abstract][Full Text] [Related]
16. Longitudinal changes in LIC and other parameters in patients receiving different chelation regimens: Data from LICNET.
Vitrano A; Sacco M; Rosso R; Quota A; Fiorino D; Oliva E; Gerardi C; Roccamo G; Spadola V; Filosa A; Tesé L; Calvaruso G; Pitrolo L; Mistretta L; Cassarà F; Di Maggio R; Maggio A
Eur J Haematol; 2018 Feb; 100(2):124-130. PubMed ID: 29094403
[TBL] [Abstract][Full Text] [Related]
17. Persistence and compliance of deferoxamine versus deferasirox in Medicaid patients with sickle-cell disease.
Jordan LB; Vekeman F; Sengupta A; Corral M; Guo A; Duh MS
J Clin Pharm Ther; 2012 Apr; 37(2):173-81. PubMed ID: 21592159
[TBL] [Abstract][Full Text] [Related]
18. Deferasirox improves hematologic and hepatic function with effective reduction of serum ferritin and liver iron concentration in transfusional iron overload patients with myelodysplastic syndrome or aplastic anemia.
Cheong JW; Kim HJ; Lee KH; Yoon SS; Lee JH; Park HS; Kim HY; Shim H; Seong CM; Kim CS; Chung J; Hyun MS; Jo DY; Jung CW; Sohn SK; Yoon HJ; Kim BS; Joo YD; Park CY; Min YH;
Transfusion; 2014 Jun; 54(6):1542-51. PubMed ID: 24313463
[TBL] [Abstract][Full Text] [Related]
19. Biopsy-based calibration of T2* magnetic resonance for estimation of liver iron concentration and comparison with R2 Ferriscan.
Garbowski MW; Carpenter JP; Smith G; Roughton M; Alam MH; He T; Pennell DJ; Porter JB
J Cardiovasc Magn Reson; 2014 Jun; 16(1):40. PubMed ID: 24915987
[TBL] [Abstract][Full Text] [Related]
20. Multicenter validation of spin-density projection-assisted R2-MRI for the noninvasive measurement of liver iron concentration.
St Pierre TG; El-Beshlawy A; Elalfy M; Al Jefri A; Al Zir K; Daar S; Habr D; Kriemler-Krahn U; Taher A
Magn Reson Med; 2014 Jun; 71(6):2215-23. PubMed ID: 23821350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
